Tolerability of the triptans: Clinical implications

Giuseppe Nappi, Giorgio Sandrini, Grazia Sances

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

The triptans represent a relatively new class of compounds effective in the treatment of migraine. The safety and tolerability of these drugs have been extensively investigated since the first triptan (sumatriptan) became commercially available. A report on a very large population of patients tested during clinical trials and in postmarketing studies, confirms that these drugs are safe and well tolerated when correctly used. Adverse events are frequently reported, but are usually mild and only a few patients discontinue therapy because of them. These adverse events include, in particular, the so-called 'triptan symptoms' (tingling, sensation of warmth, etc.). The exact mechanism of chest symptoms reported by 20% of patients with migraine treated with triptans remains unclear, but are exceptionally related to a cardiac mechanism. CNS adverse events (i.e. somnolence) are also reported, but it is a matter of debate whether they are related to the pharmacological properties (i.e. lipophilicity) of the drug or are symptoms of the disease itself. The potential risk for drug overuse must be taken into account when the triptans are given to patients with a high frequency of migraine attacks. Clinical interaction of triptans with other drugs metabolised in the liver may theoretically influence the incidence of adverse events, but there is little evidence to support this assumption. There is no evidence of a teratogenic risk of triptans in pregnant women taking these drugs.

Original languageEnglish
Pages (from-to)93-107
Number of pages15
JournalDrug Safety
Volume26
Issue number2
DOIs
Publication statusPublished - 2003

Fingerprint

Tryptamines
Migraine Disorders
Pharmaceutical Preparations
Sumatriptan
Liver
Pregnant Women
Thorax
Clinical Trials
Pharmacology
Safety
Incidence
Therapeutics

ASJC Scopus subject areas

  • Health, Toxicology and Mutagenesis
  • Public Health, Environmental and Occupational Health
  • Pharmacology
  • Toxicology

Cite this

Tolerability of the triptans : Clinical implications. / Nappi, Giuseppe; Sandrini, Giorgio; Sances, Grazia.

In: Drug Safety, Vol. 26, No. 2, 2003, p. 93-107.

Research output: Contribution to journalArticle

Nappi, Giuseppe ; Sandrini, Giorgio ; Sances, Grazia. / Tolerability of the triptans : Clinical implications. In: Drug Safety. 2003 ; Vol. 26, No. 2. pp. 93-107.
@article{b0576b7819af45899d690949ff95ab39,
title = "Tolerability of the triptans: Clinical implications",
abstract = "The triptans represent a relatively new class of compounds effective in the treatment of migraine. The safety and tolerability of these drugs have been extensively investigated since the first triptan (sumatriptan) became commercially available. A report on a very large population of patients tested during clinical trials and in postmarketing studies, confirms that these drugs are safe and well tolerated when correctly used. Adverse events are frequently reported, but are usually mild and only a few patients discontinue therapy because of them. These adverse events include, in particular, the so-called 'triptan symptoms' (tingling, sensation of warmth, etc.). The exact mechanism of chest symptoms reported by 20{\%} of patients with migraine treated with triptans remains unclear, but are exceptionally related to a cardiac mechanism. CNS adverse events (i.e. somnolence) are also reported, but it is a matter of debate whether they are related to the pharmacological properties (i.e. lipophilicity) of the drug or are symptoms of the disease itself. The potential risk for drug overuse must be taken into account when the triptans are given to patients with a high frequency of migraine attacks. Clinical interaction of triptans with other drugs metabolised in the liver may theoretically influence the incidence of adverse events, but there is little evidence to support this assumption. There is no evidence of a teratogenic risk of triptans in pregnant women taking these drugs.",
author = "Giuseppe Nappi and Giorgio Sandrini and Grazia Sances",
year = "2003",
doi = "10.2165/00002018-200326020-00003",
language = "English",
volume = "26",
pages = "93--107",
journal = "Drug Safety",
issn = "0114-5916",
publisher = "Adis International Ltd",
number = "2",

}

TY - JOUR

T1 - Tolerability of the triptans

T2 - Clinical implications

AU - Nappi, Giuseppe

AU - Sandrini, Giorgio

AU - Sances, Grazia

PY - 2003

Y1 - 2003

N2 - The triptans represent a relatively new class of compounds effective in the treatment of migraine. The safety and tolerability of these drugs have been extensively investigated since the first triptan (sumatriptan) became commercially available. A report on a very large population of patients tested during clinical trials and in postmarketing studies, confirms that these drugs are safe and well tolerated when correctly used. Adverse events are frequently reported, but are usually mild and only a few patients discontinue therapy because of them. These adverse events include, in particular, the so-called 'triptan symptoms' (tingling, sensation of warmth, etc.). The exact mechanism of chest symptoms reported by 20% of patients with migraine treated with triptans remains unclear, but are exceptionally related to a cardiac mechanism. CNS adverse events (i.e. somnolence) are also reported, but it is a matter of debate whether they are related to the pharmacological properties (i.e. lipophilicity) of the drug or are symptoms of the disease itself. The potential risk for drug overuse must be taken into account when the triptans are given to patients with a high frequency of migraine attacks. Clinical interaction of triptans with other drugs metabolised in the liver may theoretically influence the incidence of adverse events, but there is little evidence to support this assumption. There is no evidence of a teratogenic risk of triptans in pregnant women taking these drugs.

AB - The triptans represent a relatively new class of compounds effective in the treatment of migraine. The safety and tolerability of these drugs have been extensively investigated since the first triptan (sumatriptan) became commercially available. A report on a very large population of patients tested during clinical trials and in postmarketing studies, confirms that these drugs are safe and well tolerated when correctly used. Adverse events are frequently reported, but are usually mild and only a few patients discontinue therapy because of them. These adverse events include, in particular, the so-called 'triptan symptoms' (tingling, sensation of warmth, etc.). The exact mechanism of chest symptoms reported by 20% of patients with migraine treated with triptans remains unclear, but are exceptionally related to a cardiac mechanism. CNS adverse events (i.e. somnolence) are also reported, but it is a matter of debate whether they are related to the pharmacological properties (i.e. lipophilicity) of the drug or are symptoms of the disease itself. The potential risk for drug overuse must be taken into account when the triptans are given to patients with a high frequency of migraine attacks. Clinical interaction of triptans with other drugs metabolised in the liver may theoretically influence the incidence of adverse events, but there is little evidence to support this assumption. There is no evidence of a teratogenic risk of triptans in pregnant women taking these drugs.

UR - http://www.scopus.com/inward/record.url?scp=0037275120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037275120&partnerID=8YFLogxK

U2 - 10.2165/00002018-200326020-00003

DO - 10.2165/00002018-200326020-00003

M3 - Article

C2 - 12534326

AN - SCOPUS:0037275120

VL - 26

SP - 93

EP - 107

JO - Drug Safety

JF - Drug Safety

SN - 0114-5916

IS - 2

ER -